Chromai
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech firm applying CRISPR gene-editing to develop next-generation cell and gene therapies for oncology.
Oncology
Technology Platform
A proprietary suite of CRISPR-based gene-editing tools optimized for precision engineering of immune cells and for in vivo therapeutic applications in oncology.
Opportunities
Potential to address unmet needs in solid tumor treatment with edited cell therapies and benefit from China's supportive policies for innovative drug development.
Risk Factors
Faces significant scientific risks related to off-target editing effects, delivery challenges in vivo, and intense intellectual property disputes in the CRISPR field.
Competitive Landscape
Operates in a fiercely competitive global field dominated by companies like CRISPR Therapeutics, Editas Medicine, and numerous Chinese rivals such as EdiGene.